Pomegra
Celaid Therapeutics closed a ¥400 million (about $2.6 million) second Series B tranche with Shionogi and Teikoku Ventures, funding its pediatric stem-cell therapy's push toward U.S. trials.
Key Takeaways
- Celaid raised ¥400M (~$2.6M) in a Series B second close announced October 5, 2026; Shionogi and Teikoku Ventures are new investors.
- Total funding, including AMED grants, reaches about ¥3.42B (~$22.1M). Valuation is undisclosed.
- Proceeds fund manufacturing, safety work and regulatory steps for the CLD-001 IND filing with the FDA.
Lead
Celaid Therapeutics, a Tokyo-based spinout of the University of Tokyo and the University of Tsukuba, completed the second close of its Series B round on October 5, 2026. The round raised ¥400 million, roughly $2.6 million, from two new investors: Japanese drugmaker Shionogi & Co. and Teikoku Ventures, the corporate venture arm of the Teikoku Pharmaceutical group. The money is earmarked for manufacturing, safety assessment, clinical development and regulatory work needed to file an investigational new drug application for its lead program, CLD-001, in the United States.
What Is Celaid Therapeutics Building?
Celaid is building cell therapies from hematopoietic stem cells (HSCs), the blood-forming cells found in bone marrow and umbilical cord blood. Its core technology expands these cells outside the body, ex vivo, using a culture method that substitutes polyvinyl alcohol for albumin. CEO Nobuyuki Arakawa leads the company.
CLD-001 is an expanded HSC product that uses frozen umbilical cord blood as its cell source. It targets severe non-malignant pediatric diseases: primary immunodeficiency, congenital metabolic disorders, aplastic anemia and sickle cell disease. Cord blood is a practical source but contains limited cell numbers. Expansion is meant to address that constraint.
How Big Is This Round, and Who Is Behind It?
The second close is small: ¥400 million is about a fifth of the cumulative figure that includes grants and far below what a clinical-stage cell therapy typically needs. Celaid has not disclosed a valuation or named a lead investor for this tranche. The new investors are strategic rather than financial, which matters more than the cheque size.
The first close, announced in October 2025, totaled ¥1.055 billion, backed by venture capital firms and the Japan Agency for Medical Research and Development (AMED). Existing investors have included Osaka University Venture Capital, UTEC, Techno Science and Joyo Capital Partners. Celaid has not published how much of that first close was equity versus grant money, so the true size of the privately raised Series B is hard to pin down.
Cumulative funding, including AMED subsidies, now stands at about ¥3.42 billion, or $22.1 million. AMED support continues under Stage 3 of its drug discovery venture ecosystem program. A heavy grant share is common among Japanese academic spinouts. It also means private capital has committed less than the headline suggests.
Why Did Shionogi and Teikoku Ventures Invest?
Both are positioning for cell and gene therapy exposure without building the capability themselves. A Shionogi executive described HSC expansion as an approach that could overcome existing treatment challenges and widen access. Teikoku Ventures' chief executive called the technology foundational infrastructure for cell and gene therapy in hard-to-treat blood diseases.
The second statement is the more revealing one. HSC expansion is a platform input: gene-edited or gene-modified HSC products depend on getting enough healthy cells. Celaid lists next-generation cell and gene therapy among its goals, so a pharma partner gains an option on that platform. No licensing or collaboration terms were announced.
A minority strategic stake is also cheap for a company of Shionogi's size. At ¥400 million shared between two investors, the commitment is a signal, not a bet.
What Has Celaid Achieved Toward FDA Trials?
Celaid has completed a pre-IND meeting with the FDA, the agency's informal consultation before a formal application. It has established its manufacturing process and finished technology transfer to a U.S. contract development and manufacturing organization. It also reports supportive efficacy and safety data from animal models.
These are preparatory steps, not clinical evidence. No human data for CLD-001 have been disclosed, and the company has not announced a filing date or first-patient timeline. The risks that remain are conventional for cell therapy: manufacturing consistency at clinical scale, safety of expanded cells, and the cost of a pediatric trial in rare diseases with small patient pools.
What Comes Next for Celaid?
The next milestone is the IND submission, after which the FDA has 30 days to clear a trial or place it on hold. The ¥400 million will not cover a clinical program on its own. A further Series B close, a partnership with one of the new strategic investors, or additional AMED funding looks necessary to move CLD-001 into patients.
The pediatric rare-disease focus offers regulatory incentives in the U.S., including potential orphan and rare pediatric designations, though Celaid has not said it will seek them. Competing approaches to expanding cord blood HSCs already exist, and Celaid's differentiation rests on its albumin-free culture method and unproven clinical performance.
Outlook
Celaid has added two pharma-linked investors, lifted cumulative funding to about ¥3.42 billion and cleared a pre-IND meeting with the FDA. Its valuation, lead investor and IND timing remain undisclosed. The next test is whether the strategic backing converts into larger financing or a partnership once the company files in the U.S. and begins pediatric dosing.
